Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of JNJ-64179375 in Healthy Men
NCT02949206Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ichorcumab in thrombosis (11 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Adverse Events (AE) as a Measure of Safety and Tolerability, Change From Baseline in Potential for Reversibility of the JNJ-64179375 Induced Pharmacodynamic Effects on Coagulation Parameters at Day 1 and 1 more. Started Nov 2016; status: completed.
02
Drugs
ichorcumab
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT02949206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949206.